COVID vs Head, Heart, and Heparin; Afib Screening Flop; Phone Triage Dangerous?
Heparin binds to cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and “potently” blocks the virus, which could open up therapy options. (Cell)
The heightened focus on post-viral effects is what’s really novel about lingering heart damage after COVID-19, a piece in The Atlantic suggests.
Nearly 2% of COVID-19 patients sustain a stroke, with “exceedingly high” 34% in-hospital mortality, a meta-analysis showed. (Neurology)
Opportunistic screening for atrial fibrillation (Afib) in seniors at primary care visits didn’t actually increase the detection rate in a pragmatic randomized trial in the Netherlands. (The BMJ)
Johns Hopkins Hospital turned its interactive gaming room for stroke rehabilitation into a staff decompression space during the COVID-19 lockdown.
Outcomes after MI improved, especially for women, from 2008 to 2017. (Circulation)
Sept. 21 marked the 60th anniversary of the first successful mitral valve prosthesis implant. (The Oregonian)
James T. Willerson, MD, “a giant in modern cardiology,” died last week at age 81. (Cardiovascular Business)
Semi-automatic phone triage systems used during out-of-office hours underestimated urgency in 27% of patients with acute coronary syndrome or other life-threatening events. (Open Heart)
Event risk with cumulative exposure to high cholesterol suggest it might be better to intervene before middle age and think of “cholesterol-years” akin to “pack-years” of smoking. (Journal of the American College of Cardiology [JACC])
Black heart failure patients had worse prognoses than their white peers even after achieving NT-proBNP-based treatment goals, according to a study in Circulation.
In-stent restenosis improved substantially with contemporary drug-eluting stents but still occurs in a “considerable proportion” of patients. (JACC)
Awareness that heart disease is the leading cause of death among women declined from 2009 to 2019, particularly for minorities and younger women. (Circulation)
The absorbable Tyrx antibacterial envelope for cardiac implantable devices could be considered cost-effectiveness at $112,603 per quality-adjusted life-year gained. (Circulation: Arrhythmia and Electrophysiology)
The second-generation AcQMap 3D imaging and mapping catheter got FDA clearance, Acutus Medical announced.
Abbott said its next-generation MitraClip G4 got the greenlight from European regulators.
The British National Institute for Health and Care Excellence issued a positive recommendation for volanesorsen (Waylivra) as familial chylomicronemia syndrome therapy, Akcea announced.
Adaptive cardiac resynchronization therapy (CRT) wasn’t better than conventional CRT for electrical dyssynchrony in a small trial reported on the medRxiv preprint server.
Exosomes from human-induced pluripotent stem cell-derived cardiac cells improved MI recovery in pigs. (BioWorld)